Showing results (91-100 of 1,295) with videos related to

Sort By:
Pageof 130
Clinical Journal of the American Society of Nephrology : CJASN|November 2, 2019
Varying Association of Extended Hours Dialysis with Quality of LifeBrendan Smyth, Oliver van den Broek-Best, Daqing Hong, et al.
Kidney & Blood Pressure Research|April 17, 2003
Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cellsVlado Perkovic, Timothy D Hewitson, Kristen J Kelynack, et al.
Kidney International Reports|February 22, 2021
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin ReceptorMegumi Oshima, Akinori Hara, Tadashi Toyama, et al.
Journal of Hypertension|May 21, 2010
Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trialToshiharu Ninomiya, Sophia Zoungas, Bruce Neal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 14, 2014
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trialDavid W Johnson, Elaine M Pascoe, Sunil V Badve, et al.
Nephrology (Carlton, Vic.)|October 30, 2022
Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended reviewBenjamin Talbot, Alan Cass, Robert Walker, et al.
The Lancet. Diabetes & Endocrinology|March 25, 2016
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysisJason H Y Wu, Celine Foote, Juuso Blomster, et al.
Clinical Kidney Journal|July 5, 2021
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) ProgramMatthew R Weir, April Slee, Tao Sun, et al.
Plos One|September 13, 2017
Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysisSong Ren, Ying Wang, Li Xian, et al.
Diabetes Care|September 13, 2013
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunctionPer-Henrik Groop, Mark E Cooper, Vlado Perkovic, et al.
Pageof 130